DuChemBIO Co., Ltd.

As of June 30, 2026, DuChemBIO Co., Ltd. carries a market capitalization of 177.93B, placing it among publicly traded companies globally. Its enterprise value stands at 179.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DuChemBIO Co., Ltd.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, DuChemBIO Co., Ltd. has 28.38M shares outstanding.

As of June 30, 2026, DuChemBIO Co., Ltd. trades at a trailing price-to-earnings ratio of 26.04. The price-to-sales ratio is 4.28, and the price-to-book ratio stands at 3.45.

As of June 30, 2026, DuChemBIO Co., Ltd. trades at an EV/EBITDA multiple of 10.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. DuChemBIO Co., Ltd. trades at an EV/FCF ratio of 13.66, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 179.65B versus a market cap of 177.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, DuChemBIO Co., Ltd. maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.23, indicating elevated leverage, while an interest coverage ratio of 12.37 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, DuChemBIO Co., Ltd. posted a return on equity (ROE) of 14.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.41 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.18, useful for judging operating efficiency across full business cycles. The company generates approximately 289.77M in revenue per employee across its workforce of 143.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 18.32 indicates how many times DuChemBIO Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, DuChemBIO Co., Ltd. recorded 344.14M in income tax expense. That works out to an effective tax rate of 4.80, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.17B, leaving 6.83B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, DuChemBIO Co., Ltd.'s stock has declined approximately 18.31% over the past 52 weeks. The 50-day moving average sits at 6,779.80, while the 200-day moving average is 7,911.70.

Over the twelve months ended June 30, 2026, DuChemBIO Co., Ltd. generated 41.51B in revenue and converted that into 6.83B in net income, yielding earnings per share of 240.47. EBITDA reached 16.80B, while operating income came in at 8.07B.

As of June 30, 2026, DuChemBIO Co., Ltd. holds 19.03B in cash and equivalents against 20.75B in total debt, resulting in a net debt position of -13.16B. Total book value stands at 51.57B, with working capital of 14.70B providing operational flexibility.

DuChemBIO Co., Ltd. produced 12.64B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -785.39M in capital expenditures, free cash flow totaled 11.86B - equivalent to 418.25 per share.

Over the twelve months ended June 30, 2026, DuChemBIO Co., Ltd. posted a gross margin of 37.81, reflecting its pricing power and cost economics. The operating margin of 19.45 and net profit margin of 16.45 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.66, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to DuChemBIO Co., Ltd. shareholders.

As of June 30, 2026, DuChemBIO Co., Ltd. has an Altman Z-Score of 5.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.